Abstract Details
|
Michael J. Lyerly, MD, FAAN
(University of Alabama At Birmingham)
PRESENTER |
Dr. Lyerly has nothing to disclose. |
| Dawn W. Langdon, PhD (Royal Holloway) | Prof. Langdon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Prof. Langdon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. The institution of Prof. Langdon has received research support from Merck. The institution of Prof. Langdon has received research support from Novartis. The institution of Prof. Langdon has received research support from MS Society (UK). The institution of Prof. Langdon has received research support from Multiple Sclerosis Trust (UK). |
| Karen C. Albright, DO, DO, PhD, MS, MPH (FDA) | Dr. Albright has nothing to disclose. |
| No disclosure on file | |
| Kara A. Sands, MD (University of Alabama at Birmingham, Department of Neurology) | Dr. Sands has nothing to disclose. |
| Harn Shiue, PharmD (Mayo Clinic Arizona Hospital) | Dr. Shiue has nothing to disclose. |
| No disclosure on file | |
| No disclosure on file |